After a three year stretch where Novo Nordisk stock has declined 50.5%, the valuation picture now looks more supportive than the share price performance suggests, helped by a strong set of value checks even as recent news has weighed on sentiment.
- The 50.5% fall over three years has reset expectations and leaves investors asking whether the current price already reflects concerns around the business.
- The failed ZEUS trial for ziltivekimab may cap confidence in Novo Nordisk's pipeline driven growth potential, while ongoing legal disputes such as the GLP-1 advertising lawsuit with Eli Lilly can add headline risk to how the market prices the stock.
- Novo Nordisk screens as undervalued on 5 of 6 valuation checks, which suggests the broader fundamentals based metrics lean cheap compared with the current share price.
The issue now is whether the current valuation of Novo Nordisk offers enough compensation for the clinical and competitive risks that have come back into focus.
Find out why Novo Nordisk's -3.1% return over the last year is lagging behind its peers.
Is Novo Nordisk a Bargain on Earnings?
The P/E ratio is a useful way to think about what you are paying today for each dollar of Novo Nordisk earnings. On this metric, Novo Nordisk currently trades on about 11.2x earnings, which is below both the Pharmaceuticals industry average of roughly 15.6x and a broader peer group average of 44.2x.
A more tailored fair P/E that factors in Novo Nordisk size, margins and risk profile sits higher at about 24.5x. This is more than double the current 11.2x level, which indicates a sizeable gap between what the model suggests investors might usually pay and where the stock actually trades. Despite the recent ZEUS trial setback and the GLP-1 advertising lawsuit with Eli Lilly, the market multiple still prices Novo Nordisk at a discount to these benchmarks.
Overall, Novo Nordisk appears undervalued on its current P/E multiple relative to both the industry and the modelled fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Novo Nordisk Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Novo Nordisk valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to occur for the stock to be worth significantly more or less than today’s price, based on scenarios shared on the Community page. Each narrative ties a fair value estimate to a clear story about Novo Nordisk's potential catalysts and risks so you can track which version seems to be unfolding over time.
One of the top community narratives on Novo Nordisk: 53% undervalued
"Current sentiment has swung deeply negative, but expectations are now low, and the embedded upside is material if execution is even moderate…"
Read one of the top narratives on Novo Nordisk
Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!
The Bottom Line
Novo Nordisk looks undervalued on the current P/E based checks, even after factoring in sentiment damage from the ZEUS trial outcome and the GLP-1 advertising lawsuit with Eli Lilly. The key question for you is whether that discount is compensation for real clinical and competitive risk or an opportunity if the core franchises and pipeline can meet already reduced expectations. The debate now largely hinges on how much confidence you have that earnings resilience and future products can support a higher multiple over time, rather than the stock remaining priced as a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com